Companies / RGT

ARGENT BIOPHARMA LIMITED

ASX:RGTPharmaceuticals, Biotechnology & Life Sciences
116.6M shares on issueASX (delayed) · as of 28 July 2026$0.050price · delayed$5.8Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 141% in 24 months; 4 cash raises in 24 months

Cash runway0.5 quarters of funding
Share-count growth (24m)140.9%
Raise cadence (24m)4 cash raises
Options & rights overhang82.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

ARGENT BIOPHARMA LIMITED's ordinary share count grew 140.9% between July 2024 and July 2026, to 117M shares. The company raised capital four times in that period for total disclosed proceeds of A$7.5M, most recently an "A$11m Financing Agreement (convertible notes + options)" that reported proceeds of A$350K in July 2026. Options and rights on issue could convert into 97M new shares, equal to 82.9% of the current share count, with the nearest expiry in July 2026 and 0% of current shares in the money. At the June 2026 quarter the company reported A$308K in available cash, covering about 0.5 quarters. One proposed securities issue (Appendix 3B) is pending, with an expected issue date in November 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
82.9%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
0.5 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 116.6M per ASX (delayed) (28 July 2026).
67.4M85.4M103.5MDec 24Sept 25July 26Cash raise · 14 July 2026Cash raise · 23 Apr 2025Cash raise · 2 Jan 2025

Cash runway

0.5 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$308k available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
17 July 20263H · cancellationRGT : ORDINARY FULLY PAID116.6MAppendix 3H
14 July 20263G · unquotedRGT : ORDINARY FULLY PAID116.6MAppendix 3G
8 July 20262A · quoted issueRGT : ORDINARY FULLY PAID116.6MAppendix 2A
10 Apr 20262A · quoted issueRGT : ORDINARY FULLY PAID90.9MAppendix 2A
10 Apr 20262A · quoted issueRGT : ORDINARY FULLY PAID89.4MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 1 in the last 12 months

$350k
A$11m Financing Agreement (convertible notes + options)
14 July 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

82.9%
Total overhang · of current shares
0.0%
In the money · at current price
96.7M
Potential new shares
July 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
10 Apr 2026Daniel RobinsonOther500k120k—3Y notice
10 Apr 2026Roby Reuven ZomerOther6.0M——3Y notice
10 Apr 2026Gary HermonOther500k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
17 July 2026Notification of cessation of securities - RGT
14 July 2026s708A(12C)(e) Cleansing Notice
14 July 2026Notification regarding unquoted securities - RGT
14 July 2026Proposed issue of securities - RGT
14 July 2026$350,000 in Funding Received under Financing Facility
8 July 2026Application for quotation of securities - RGT
6 July 2026$PRGT Executes Global CannEpil Licensing Deal for US$5.5M
24 May 2026Long Term Aquiol Licensing and Supply Agreement
5 May 2026Final Director's Interest Notice - GH
5 May 2026Initial Director's Interest Notice - AC
5 May 2026Appointment of Executive Director
28 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
12 Apr 2026Completion of CannPal Asset Acquisition and Neuvis Option
10 Apr 2026Change of Director's Interest Notice x 3
10 Apr 2026s708A Cleansing Notice
10 Apr 2026Notification regarding unquoted securities - RGT
10 Apr 2026Application for quotation of securities - RGT
10 Apr 2026Application for quotation of securities - RGT
10 Apr 2026Application for quotation of securities - RGT

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.